相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma
Brent A. Willobee et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial
Erika Martinelli et al.
JAMA ONCOLOGY (2021)
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
C. M. Parseghian et al.
ANNALS OF ONCOLOGY (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
John H. Strickler et al.
CANCER DISCOVERY (2018)
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
Jin Zhou et al.
NATURE COMMUNICATIONS (2017)
Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Loren Michel et al.
ORAL ONCOLOGY (2016)
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
Michael S. Lee et al.
ONCOTARGET (2016)
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
M. P. Morelli et al.
ANNALS OF ONCOLOGY (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
Sandra Misale et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
Sandra Misale et al.
CANCER DISCOVERY (2014)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D. Santini et al.
ANNALS OF ONCOLOGY (2012)
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N. Kwong et al.
NATURE MEDICINE (2012)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
分享论文
